33. Clinical benefit table: Hylan G‐F 20 versus NSAID. Continuous outcome measures.

Study	TIme	Treatment	Outcome (scale)	N of pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Adams 1995	14‐26 wk	E: Hylan G‐F 20	Pain on motion (0‐100 mm VAS)	29	61	40	‐10 (I)	‐15.9% (I)
		C: NSAID		33	63	52
Adams 1995	14‐26 wk	E: Hylan G‐F 20	Pain at night (0‐100 mm VAS)	29	35	25	‐4 (I)	‐11.7% (I)
		C: NSAID		33	34	28
Adams 1995	14‐26 wk	E: Hylan G‐F 20	Pain at rest (0‐100 mm VAS)	29	36	25	‐4 (I)	‐13.8% (I)
		C: NSAID		33	29	22
Adams 1995	14‐26 wk	E: Hylan G‐F 20	Pain overall (0‐100 mm VAS)	29	62	47	‐5 (I)	‐8.1% (I)
		C: NSAID		33	62	52
Dickson 2001	5‐13 wk	E: Hylan G‐F 20	WOMAC pain (0‐100 mm VAS)	53	59	26	‐10 (I)	‐16.4% (I)
		C: Diclofenac		55	61	38
Dickson 2001	5‐13 wk	E: Hylan G‐F 20	WOMAC function (0‐100 mm VAS)	53	54	38	‐2 (I)	‐3.6% (I)
		C: Diclofenac		55	56	42
Dickson 2001	5‐13 wk	E: Hylan G‐F 20	Lequesne Index (0‐24)	53	13.9	10.9	‐1 (I)	‐7.2% (I)
		C: Diclofenac		55	13.9	11.9
Adams 1995	5‐13 wk	E: Hylan G‐F 20 + NSAID	Pain on motion (0‐100 mm VAS)	34	60	34	‐7 (I)	‐11.1% (I)
		C: NSAID		33	63	44
Adams 1995	5‐13 wk	E: Hylan GF 20 + NSAID	Pain at night (0‐100 mm VAS)	34	20	10	3 (W)	8.8% (W)
		C: NSAID		33	34	21
Adams 1995	5‐13 wk	E: Hylan G‐F 20 + NSAID	Pain at rest (0‐100 mm VAS)	34	26	14	‐3 (I)	‐10.3% (I)
		C: NSAID		33	29	20
Adams 1995	5‐13 wk	E: Hylan G‐F 20 + NSAID	Pain overall (0‐100 mm VAS)	34	57	31	‐7 (I)	‐11.3% (I)
		C: NSAID		33	62	43
Adams 1995	14‐26 wk	E: Hylan G‐F 20 + NSAID	Pain on motion (0‐100 mm VAS)	32	60	37	‐12 (I)	‐19% (I)
		C: NSAID		31	63	52
Adams 1995	14‐26 wk	E: Hylan G‐F 20 + NSAID	Pain at night (0‐100 mm VAS)	32	20	9	‐5 (I)	‐14.7% (I)
		C: NSAID		31	34	28
Adams 1995	14‐26 wk	E: Hylan G‐F 20 + NSAID	Pain at rest (0‐100 mm VAS)	32	26	11	‐8 (I)	‐27.6% (I)
		C: NSAID		31	29	22
Adams 1995	14‐26 wk	E: Hylan G‐F 20 + NSAID	Pain overall (0‐100 mm VAS)	32	57	37	‐10 (I)	‐16.1% (I)
		C: NSAID		31	62	52